Target Name: USP17L5
NCBI ID: G728386
Other Name(s): ubiquitin thioesterase 17-like protein 5 | U17L5_HUMAN | ubiquitin specific peptidase 17 like family member 5 | ubiquitin-specific-processing protease 17-like protein 5 | Ubiquitin-specific-processing protease 17-like protein 5 | Deubiquitinating enzyme 17-like protein 5 | Ubiquitin thiolesterase 17-like protein 5 | ubiquitin thiolesterase 17-like protein 5 | Ubiquitin specific peptidase 17 like family member 5 | Ubiquitin carboxyl-terminal hydrolase 17-like protein 5 | Ubiquitin thioesterase 17-like protein 5 | deubiquitinating enzyme 17-like protein 5

USP17L5: A Potential Drug Target and Biomarker

Ubiquitin thioesterase 17-like protein 5 (USP17L5) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and liver. USP17L5 plays a critical role in the regulation of protein degradation, which is a process that is essential for maintaining cellular homeostasis. Mutations in the USP17L5 gene have been linked to a range of disorders, including neurodegenerative diseases, developmental delays, and autoimmune diseases.

In recent years, researchers have become increasingly interested in USP17L5 as a potential drug target and biomarker. USP17L5 has been shown to play a role in a number of cellular processes that are important for human health, including the regulation of protein homeostasis, inflammation, and cell survival. As a result, USP17L5 has emerged as a promising target for drug development.

One of the key advantages of USP17L5 as a drug target is its expressedness in a wide range of tissues, including the brain. This makes it an attractive target for drugs that can modulate its activity and potentially affect the expression of other genes. Additionally, USP17L5 has been shown to play a role in the regulation of protein degradation, which is a critical process for maintaining cellular homeostasis. This means that drugs that can modulate its activity may have a wide range of potential applications, including the treatment of a variety of diseases.

Another promising aspect of USP17L5 is its role in the regulation of inflammation. USP17L5 has been shown to play a role in the production of reactive oxygen species (ROS), which are highly reactive molecules that can cause damage to cells and contribute to the development of inflammatory diseases. By targeting USP17L5, drugs that can modulate its activity may be able to reduce the production of ROS and potentially treat a variety of inflammatory disorders.

In addition to its potential as a drug target, USP17L5 has also been shown to be a potential biomarker for a number of diseases. For example, USP17L5 has been shown to be expressed in the brains of individuals with Alzheimer's disease, which is a leading cause of dementia. This suggests that USP17L5 may be a useful biomarker for the diagnosis and treatment of Alzheimer's disease. Additionally, USP17L5 has been shown to be expressed in the blood vessels of individuals with cardiovascular disease, which suggests that it may be a useful biomarker for the diagnosis and treatment of cardiovascular disease.

Overall, USP17L5 is a protein that has the potential to be a drug target and biomarker. Its expressedness in a wide range of tissues, including the brain, makes it an attractive target for drugs that can modulate its activity. Its role in the regulation of protein homeostasis and inflammation also makes it a promising target for drugs that can treat a variety of disorders. Further research is needed to fully understand the potential of USP17L5 as a drug target and biomarker.

Protein Name: Ubiquitin Specific Peptidase 17 Like Family Member 5

Functions: Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes that may include cell proliferation, progression through the cell cycle, apoptosis, cell migration, and the cellular response to viral infection

More Common Targets

USP17L6P | USP17L7 | USP17L8 | USP17L9P | USP18 | USP19 | USP2 | USP2-AS1 | USP20 | USP21 | USP22 | USP24 | USP25 | USP26 | USP27X | USP27X-DT | USP28 | USP29 | USP3 | USP3-AS1 | USP30 | USP30-AS1 | USP31 | USP32 | USP32P1 | USP32P2 | USP32P3 | USP33 | USP34 | USP35 | USP36 | USP37 | USP38 | USP39 | USP4 | USP40 | USP41 | USP42 | USP43 | USP44 | USP45 | USP46 | USP46-DT | USP47 | USP48 | USP49 | USP5 | USP50 | USP51 | USP53 | USP54 | USP6 | USP6NL | USP6NL intronic transcript 1 (non-protein coding), transcript variant 1 | USP7 | USP8 | USP8P1 | USP9X | USP9Y | USPL1 | UST | UTF1 | UTP11 | UTP14A | UTP14C | UTP15 | UTP18 | UTP20 | UTP23 | UTP25 | UTP3 | UTP4 | UTP6 | UTRN | UTS2 | UTS2B | UTS2R | UTY | UVRAG | UVSSA | UXS1 | UXT | UXT-AS1 | VAC14 | Vacuolar H+ ATPase | VAMP1 | VAMP2 | VAMP3 | VAMP4 | VAMP5 | VAMP7 | VAMP8 | VANGL1 | VANGL2 | VAPA | VAPB | VARS1 | VARS2 | Vascular endothelial growth factor receptor (VEGFR) | Vascular endothelial growth factors (VEGF)